MASLD como enfermedad crónica sistémica: integrando hígado y riñón en un mismo paradigma
DOI:
https://doi.org/10.59093/27112330.171Palabras clave:
enfermedad hepática esteatósica asociada a disfunción metabólica (MASLD), enfermedad renal crónica, albuminuria, síndrome cardiorrenometabólico, lipotoxicidad, resistencia a la insulina.Resumen
La enfermedad hepática esteatósica asociada a disfunción metabólica (MASLD) ha dejado de entenderse como una alteración confinada al hígado para consolidarse como una entidad sistémica con repercusiones cardiovasculares, metabólicas y renales, con una prevalencia cada vez más elevada a nivel mundial. Así mismo, la enfermedad renal crónica (ERC) continúa aumentando en todo el mundo, impulsada en gran medida por la obesidad, la resistencia a la insulina, la diabetes tipo 2 y otras expresiones del síndrome cardiovascular-reno-metabólico. En este contexto, la coexistencia entre MASLD y ERC no parece obedecer únicamente a factores de riesgo compartidos, sino a mecanismos biológicos convergentes que favorecen la lesión glomerular y tubular, la inflamación persistente, el estrés oxidativo, la lipotoxicidad, la activación neurohormonal y la fibrosis progresiva. Esta revisión analiza la relación entre MASLD y ERC desde una perspectiva clínica, con énfasis en los ejes fisiopatológicos compartidos y las implicaciones diagnósticas y terapéuticas. Reconocer esta interacción no solo mejora la estratificación del riesgo, sino que también abre la puerta a estrategias de intervención más tempranas y multidimensionales.
Descargas
Referencias bibliográficas
Mark PB, Stafford LK, Grams ME, Aalruz H, ElHafeez SA, Abdelgalil AA, et al. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. The Lancet 2025;40:2461-2482. https://doi.org/10.1016/S0140-6736(25)01853-7.
Correa-Rotter R, Méndez-Durán A, Vallejos A, Rico-Fontalvo J, Cusumano AM, Rosa-Diez GJ, et al. Unmet needs of CKD in Latin America: A Review from Expert Virtual Working Group. Kidney Int Rep 2023;8:954-967. https://doi.org/10.1016/j.ekir.2023.02.1082.
Rico-Fontalvo J, Elbert A, Lorca E, Daza-Arnedo R, Castellaro C, Villavicencio V, et al. Situación de la enfermedad renal crónica en América Latina, con énfasis en la enfermedad renal diabética: dificultades y desafíos. Nefro Latinoam 2025;22:31-40. https://doi.org/10.24875/nefro.m24000055.
Cueto-Manzano AM, Carlino-Bauza MC, Ríos-Sarro PG, Vallejos AC, Martín CAZS, Zúñiga-Saravia EA, et al. Kidney health programs in Latin America: Results of the SLANH survey 2024. Semin Nephrol 2025;45:151606. https://doi.org/10.1016/j.semnephrol.2025.151606.
Calice-Silva V, Neyra JA, Ferreiro-Fuentes A, Singer-Wallbach Massai KK, Arruebo S, Bello AK, et al. Capacity for the management of kidney failure in the International Society of Nephrology Latin America region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA). Kidney Int Suppl 2024;13:43-56. https://doi.org/10.1016/j.kisu.2024.01.001.
Zheng H, Sechi LA, Navarese EP, Casu G, Vidili G. Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: A comprehensive review. Cardiovasc Diabetol 2024;23:346.https://doi.org/10.1186/s12933-024-02434-5.
Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol 2024;29:101133. https://doi.org/10.1016/j.aohep.2023.101133.
Fontalvo JR, Arnedo RD, Sarabia MR, Jiménez J, Montejo-Hernández J, Rodríguez-Yánez T, et al. Metabolic kidney disease: A new concept in the interaction between obesity, prediabetes, diabetes and liver dysfunction. G Ital Nefrol 2026;43:2026-vol1. https://doi.org/10.69097/43-01-2026-06.
Iturbe-Rey S, Maccali C, Arrese M, Aspichueta P, Oliveira CP, Castro RE, et al. Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD). Atherosclerosis 2025;400:119053. https://doi.org/10.1016/j.atherosclerosis.2024.119053.
Ndumele CE, Neeland IJ, Tuttle KR, Chow SL, Mathew RO, Khan SS, et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: A scientific statement from the American Heart Association. Circulation 2023;148:1636-1664. https://doi.org/10.1161/CIR.0000000000001186.
Habibullah M, Jemmieh K, Ouda A, Haider MZ, Malki MI, Elzouki AN. Metabolic-associated fatty liver disease: A selective review of pathogenesis, diagnostic approaches, and therapeutic strategies. Front Med 2024;11:1291501. https://doi.org/10.3389/fmed.2024.1291501.
Kuchay MS, Choudhary NS, Ramos-Molina B. Pathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease. Am J Physiol Cell Physiol 2025;328:C1637-C1666. https://doi.org/10.1152/ajpcell.00951.2024.
Ibrahim MK, Simon TG, Rinella ME. Extrahepatic outcomes of nonalcoholic fatty liver disease: nonhepatocellular cancers. Clin Liver Dis 2023;27:251-273. https://doi.org/10.1016/j.cld.2023.01.004.
Hagström H, Kechagias S, Ekstedt M. Risk for hepatic and extra-hepatic outcomes in nonalcoholic fatty liver disease. J Intern Med 2022;292:177-189. https://doi.org/10.1111/joim.13343.
Sethasine S, Trakarnvanich T, Ruamtawee W, Treerasoradaj N, Susantitaphong P. Association of noninvasive tests of liver fibrosis with chronic kidney disease in MASLD: A systematic review and meta-analysis. Sci Rep 2025;15:42681. https://doi.org/10.1038/s41598-025-26752-0.
Agustanti N, Soetedjo NNM, Damara FA, Iryaningrum MR, Permana H, Bestari MB, et al. The association between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: A systematic review and meta-analysis. Diabetes Metab Syndr 2023;17:102780. https://doi.org/10.1016/j.dsx.2023.102780.
Theodorakis N, Nikolaou M. From cardiovascular-kidney-metabolic syndrome to cardiovascular-renal-hepatic-metabolic syndrome: Proposing an expanded framework. Biomolecules 2025;15:213. https://doi.org/10.3390/biom15020213.
Rico-Fontalvo J, Daza-Arnedo R, Rodríguez-Yanez T, Osorio W, Suarez-Romero B, Soto O, et al. Obesidad y enfermedad renal crónica. Una mirada desde los mecanismos fisiopatológicos. REV SEN 2022;10:97-107. https://doi.org/10.56867/32.
León-Román J, López-Martínez M, Esteves A, Ciudin A, Núñez-Delgado S, Álvarez T, et al. Obesity-related kidney disease: A growing threat to renal health. Int J Mol Sci 2025;26:6641. https://doi.org/10.3390/ijms26146641.
Rico-Fontalvo J, Daza-Arnedo R, Sarabia MR, Montejo-Hernández J, Rodríguez-Yánez T, Jiménez-Quintero J, et al. Obesity and cardiorenal dysfunction: The impact of inflammation and lipotoxicity. Rev Colomb Nefrol 2026;13:e1071. https://doi.org/10.22265/acnef.13.1.1071.
Oshima M, Shimizu M, Yamanouchi M, Toyama T, Hara A, Furuichi K, et al. Trajectories of kidney function in diabetes: A clinicopathological update. Nat Rev Nephrol 2021;17:740-750. https://doi.org/10.1038/s41581-021-00462-y.
Kwon JK, Kim M, Lee J, Oh J ik, Koh JH, Kang MW, et al. Association of metabolic dysfunction-associated steatotic liver disease and kidney failure in the CKD population.Kidney Int Rep 2026;11:106414.https://doi.org/10.1016/j.ekir.2026.106414.
Qu L, Jiao B. The interplay between immune and metabolic pathways in kidney disease. Cells 2023;12:1584. https://doi.org/10.3390/cells12121584.
Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. Cardiovascular-kidney-metabolic health: A presidential advisory from the American. Circulation 2023;148:1606-1635. https://doi.org/10.1161/CIR.0000000000001184.
Bansal A, Chonchol M. Metabolic dysfunction-associated kidney disease: Pathogenesis and clinical manifestations. Kidney Int 2025;108:194-200. https://doi.org/10.1016/j.kint.2025.01.044.
Massy ZA, Drueke TB. Combination of cardiovascular, kidney, and metabolic diseases in a syndrome named cardiovascular-kidney-metabolic, with new risk prediction equations. Kidney Int Rep 2024;9:2608-2618. https://doi.org/10.1016/j.ekir.2024.05.033.
Ibrahim R, Patel D, Pham HN, Abdelnabi M, Pathangey G, Motairek I, et al. Historical redlining and cardio-kidney-metabolic disease risk factors, prevalence, and outcomes: A scoping review. JACC Adv 2025;4:101830.https://doi.org/10.1016/j.jacadv.2025.101830.
Ismail B, Nabilou P, Gluud LL, Møller S. Cardiovascular implications of MASLD: overview of the evidence. Scand J Gastroenterol 2025;60:910-918. https://doi.org/10.1080/00365521.2025.2536585.
Sandireddy R, Sakthivel S, Gupta P, Behari J, Tripathi M, Singh BK. Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases. Front Cell Dev Biol 2024;12:1433857. https://doi.org/10.3389/fcell.2024.1433857.
Sriperumbuduri S, Saravanan PB, Gupta G, Sanyal A. The metabolic dysfunction–associated steatotic liver disease–CKD axis: intersecting pathways and opportunities for early intervention. Kidney Int Rep 2025;11:103757. https://doi.org/10.1016/j.ekir.2025.103757.
Kyhl LK, Nordestgaard BG, Tybjærg-Hansen A, Nielsen SF. Metabolic dysfunction-associated steatotic liver disease, cardiometabolic risk factors, and cardiovascular disease. Atherosclerosis 2025;411:120551. https://doi.org/10.1016/j.atherosclerosis.2025.120551.
Ren L, Cui H, Wang Y, Ju F, Cai Y, Gang X, et al. The role of lipotoxicity in kidney disease: From molecular mechanisms to therapeutic prospects. Biomed Pharmacother 2023;161:114465. https://doi.org/10.1016/j.biopha.2023.114465.
Tsioufis C, Tatsis I, Thomopoulos C, Wilcox C, Palm F, Kordalis A, et al. effects of hypertension, diabetes mellitus, obesity and other factors on kidney haemodynamics. Curr Vasc Pharmacol 2014;12:537-548. https://doi.org/10.2174/157016111203140518173700.
Rüster C, Wolf G. The Role of the Renin-Angiotensin-Aldosterone System in Obesity-Related Renal Diseases. Semin Nephrol 2013;33:44-53. https://doi.org/10.1016/j.semnephrol.2012.12.002.
Godoy-Matos AF, Valério CM, Júnior WSS, de Araujo-Neto JM, Sposito AC, Suassuna JHR. CARDIAL-MS (CArdio-Renal-DIAbetes-Liver-Metabolic Syndrome): a new proposition for an integrated multisystem metabolic disease. Diabetol Metab Syndr 2025;17:218. https://doi.org/10.1186/s13098-025-01796-4.
Goh RSJ, Koh J, Intaran MAU, Chin Y, Kong G, Chong B, et al. Population-based study on the coexistence of metabolic dysfunction-associated steatotic liver disease and chronic kidney disease Am Heart Assoc 2025;14:e041834. https://doi.org/10.1161/JAHA.125.041834.
Heo JH, Lee MY, Kim SH, Zheng MH, Byrne CD, Targher G, et al. Comparative associations of non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease with risk of incident chronic kidney disease: a cohort study. Hepatobiliary Surg Nutr 2024;13:801-813. https://doi.org/10.21037/hbsn-23-558.
Gao J, Li Y, Zhang Y, Zhan X, Tian X, Li J, et al. Severity and remission of metabolic dysfunction–Associated fatty/steatotic liver disease with chronic kidney disease occurrence. J Am Heart Assoc 2024;13:e032604. https://doi.org/10.1161/JAHA.123.032604.
Yepes-Barreto I, Romero D, Coronado-Daza J. Risk factors for liver fibrosis in diabetic patients with end-stage renal disease. Rev Colomb Gastroenterol 2023;38:278–89. https://doi.org/10.22516/25007440.1061.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2026 Los autores conservan todos los derechos de autor y otorgan a la Asociación Colombiana de Hepatología un derecho no exclusivo para publicar y difundir su trabajo.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
La política de reconocimiento de autoría de Hepatología se basa en los criterios indicados por el ICMJE para conferir crédito de un trabajo a una persona, a la vez que se le atribuye responsabilidad por la publicación del mismo.
| Estadísticas de artículo | |
|---|---|
| Vistas de resúmenes | |
| Vistas de PDF | |
| Descargas de PDF | |
| Vistas de HTML | |
| Otras vistas | |
